Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast


CHERRY HILL, NJ, Aug. 15, 2022 (GLOBE NEWSWIRE) — Viant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scale biology and machine learning. Today, Vyant Bio announced that it is postponing its second quarter and first half 2022 investor conference call, originally scheduled for Monday, August 15, 2022 at 4:30 p.m. ET.

Very recent developments related to the recognition of the potential sale of its long liveThe Pharm subsidiary has required the Company to further revise its valuation estimate due to domestic and international tax considerations that may impact net sales proceeds and the resulting non-cash intangible asset impairment charge in discontinued operations and related matters resulting from these changes.

The Company will issue a press release announcing the new date and time for the postponed earnings call at the close of the call. long livePharmaceutical valuation and tax analyses.


Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapies. Vyant Bio has built a therapeutic platform aimed at treating neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett syndrome (“Rett”), CDKL5 deficiency disorders (“CDD”) and Parkinson’s disease. Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to reduce candidate screening risks, with the aim of improving potential efficacy drugs discovered earlier in the development cycle. Vyant Bio management believes that drug discovery must gradually shift to more efficient methods, as widely used models for predicting safe and effective drugs have underperformed, as evidenced by the significant time and cost to bring new medications to patients. By combining sophisticated data science capabilities with highly functional disease models derived from human cells, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to data assimilation. that supports decision-making iteratively throughout the discovery phase of drug development. to identify both new and repurposed CNS therapeutic candidates.

For more information, please visit or follow Vyant Bio on:

The Internet: www.vyantbio.com

LinkedIn: https://www.linkedin.com/company/vyant-bio

Twitter: @VyantBio

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements relating to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the effectiveness of our screening and drug discovery process, the potential sale of its long liveThe pharmaceutical subsidiary and the potential for our services, future revenues or growth in this press release constitute forward-looking statements. All statements that are not historical facts (including, but not limited to, statements containing words such as “will”, “believe”, “plan”, “anticipate”, “expect” and “esteem”) must also be taken into account. be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapting to the global coronavirus pandemic, raising capital to meet our liquidity needs, and other risks discussed in Vyant Bio, Inc.’s Form 10-K for the year ended 31 December 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

Investor contacts:

Skyline Business Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
E-mail: [email protected]


main logo

Source link


Comments are closed.